country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Referencia número: HY-108002

Copy Link Print Information

A 33903

A 33903 is a respiratory syncytial virus (RSV) replication inhibitor. A 33903 can be used for the research of RSV-infection.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS: 70890-53-8
Fòrmula: C₁₇H₁₅N₃O₂
Peso molecular:293.32

Almacenamiento:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (273 KB)

A 33903 Chemical Structure

No. CAS: 70890-53-8

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- Cellular Effect
Chemical Information
Protocolo (1)
Pureza y Documentación
Referencias
Calculators
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

A 33903 is a respiratory syncytial virus (RSV) replication inhibitor. A 33903 can be used for the research of RSV-infection^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
HEp-2	CC₅₀	>50 μM Compound: A-33903	Cytotoxicity against RSV RSS infected human Hep2 cells after 6 days by XTT assay Cytotoxicity against RSV RSS infected human Hep2 cells after 6 days by XTT assay	[PMID: 17576833]
HEp-2	EC₅₀	>100 μM Compound: A-33903	Antiviral activity against plaque picked RSV604-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay Antiviral activity against plaque picked RSV604-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	10.1 μM Compound: A-33903	Antiviral activity against RSV RSS infected human Hep2 cells assessed as reduction of viral antigen synthesis after 3 days by ELISA Antiviral activity against RSV RSS infected human Hep2 cells assessed as reduction of viral antigen synthesis after 3 days by ELISA	[PMID: 17576833]
HEp-2	EC₅₀	15.1 μM Compound: A-33903	Antiviral activity against RSV A2 infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV A2 infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	27.6 μM Compound: A-33903	Antiviral activity against plaque picked A-33903-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay Antiviral activity against plaque picked A-33903-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	3.5 μM Compound: A-33903	Antiviral activity against RSV B infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV B infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	7.2 μM Compound: A-33903	Antiviral activity against RSV Long infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV Long infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	8.1 μM Compound: A-33903	Antiviral activity against DMSO-passaged wild type RSV RSS infected human Hep2 cells by plaque reduction assay Antiviral activity against DMSO-passaged wild type RSV RSS infected human Hep2 cells by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	9.6 μM Compound: A-33903	Antiviral activity against RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay Antiviral activity against RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay	[PMID: 17576833]
HEp-2	EC₅₀	9.7 μM Compound: A-33903	Antiviral activity against RSV RSS infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV RSS infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	IC₅₀	17.6 μM Compound: 18	Antiviral activity against RSV Long in Hep2 cells by ELISA Antiviral activity against RSV Long in Hep2 cells by ELISA	[PMID: 16570927]
HEp-2	IC₅₀	17.8 μM Compound: 18	Antiviral activity against RSV B in Hep2 cells by ELISA Antiviral activity against RSV B in Hep2 cells by ELISA	[PMID: 16570927]
HEp-2	IC₅₀	3.6 μM Compound: 18	Antiviral activity against RSV B in Hep2 cells by plaque assay Antiviral activity against RSV B in Hep2 cells by plaque assay	[PMID: 16570927]
HEp-2	IC₅₀	7.1 μM Compound: 18	Antiviral activity against RSV RSS in Hep2 cells by plaque assay Antiviral activity against RSV RSS in Hep2 cells by plaque assay	[PMID: 16570927]
HEp-2	IC₅₀	7.2 μM Compound: 18	Antiviral activity against RSV Long in Hep2 cells by plaque assay Antiviral activity against RSV Long in Hep2 cells by plaque assay	[PMID: 16570927]
HEp-2	IC₅₀	8.6 μM Compound: 18	Antiviral activity against RSV RSS in Hep2 cells by whole cell XTT assay Antiviral activity against RSV RSS in Hep2 cells by whole cell XTT assay	[PMID: 16570927]
HEp-2	IC₅₀	9.3 μM Compound: 18	Antiviral activity against RSV RSS in Hep2 cells by ELISA Antiviral activity against RSV RSS in Hep2 cells by ELISA	[PMID: 16570927]
Sf9	IC₅₀	>10 μM Compound: figure 3, R4C2	Displacement of [3H]Ro15-4513 from GABAA alpha-1-beta-2-gamma-2 receptor expressed in Sf9 baculovirus system Displacement of [3H]Ro15-4513 from GABAA alpha-1-beta-2-gamma-2 receptor expressed in Sf9 baculovirus system	[PMID: 18537233]
Sf9	IC₅₀	>10 μM Compound: figure 3, R4C2	Displacement of [3H]Ro15-4513 from GABAA alpha-5-beta-2-gamma-2 receptor expressed in Sf9 baculovirus system Displacement of [3H]Ro15-4513 from GABAA alpha-5-beta-2-gamma-2 receptor expressed in Sf9 baculovirus system	[PMID: 18537233]

Chemical Information

No. CAS 70890-53-8
Peso molecular 293.32
Fòrmula C₁₇H₁₅N₃O₂
SMILES

O=C(C)NC1N=C(C2=C(NC1=O)C=CC=C2)C3=CC=CC=C3
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.

Protocolo

All Signal Pathway Related

Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (273 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Chapman J, et al. RSV604, a novel inhibitor of respiratory syncytial virus replication[J]. Antimicrobial agents and chemotherapy, 2007, 51(9): 3346-3353. [Content Brief]

Calculators

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Obtener un presupuesto En stock

Other size

Obtener un presupuesto